Cargando…

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

Immune therapy is a promising field within oncology but has been unsuccessful in ovarian cancer (OC). Still, there is rationale and evidence supporting immune therapy in OC. We investigated the potential for adoptive cell therapy (ACT) from in vitro expanded tumor-infiltrating lymphocytes (TILs) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kverneland, Anders Handrup, Pedersen, Magnus, Westergaard, Marie Christine Wulff, Nielsen, Morten, Borch, Troels Holz, Olsen, Lars Rønn, Aasbjerg, Gitte, Santegoets, Saskia J., van der Burg, Sjoerd H., Milne, Katy, Nelson, Brad H., Met, Özcan, Donia, Marco, Svane, Inge Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275789/ https://www.ncbi.nlm.nih.gov/pubmed/32547707 http://dx.doi.org/10.18632/oncotarget.27604

Ejemplares similares

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2020)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
por: Crowther, Michael D., et al.
Publicado: (2020)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
por: Kverneland, Anders H., et al.
Publicado: (2018)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Detection and functional assessment of regulatory T cells in clinical samples
por: Santegoets, Saskia, et al.
Publicado: (2014)

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
por: Draghi, Arianna, et al.
Publicado: (2021)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2019)

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2019)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Monitoring of the Immune Dysfunction in Cancer Patients
por: Santegoets, Saskia J. A. M., et al.
Publicado: (2016)

The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival
por: Santegoets, Saskia J., et al.
Publicado: (2023)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Real-world evidence to guide healthcare policies in oncology
por: Donia, Marco, et al.
Publicado: (2019)

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
por: Jespersen, Henrik, et al.
Publicado: (2017)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2017)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2020)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma
por: Kverneland, A.H., et al.
Publicado: (2023)

Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h3lgqeqerjutlpc8p1aq3j5cgc